Colorectal carcinomas that are wild type for KRAS are often sensitive to EGFR blockade [1], [3] and therefore KRAS testing can prevent both ineffective treatment and treatment-associated toxicity. This evidence concerns the gene EGFR and colorectal carcinoma.